Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Luis Ortega‐Paz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Dominick J. Angiolillo(University of Florida), Roxana Mehran(Mount Sinai Hospital), Francesco Franchi(Florida College), Gilles Montalescot(Maastricht University Medical Centre), Fabiana Rollini(Florida College), Behnood Bikdeli(Broad Institute), Mattía Galli(Maria Cecilia Hospital), Renato D. Lópes(Duke University), Davide Capodanno(University of Catania), Felicita Andreotti(Agostino Gemelli University Polyclinic), C. Michael Gibson(Baim Institute for Clinical Research)
Cited by 72
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k